News

Dr Batchelor will lead the company’s pursuit of discovering and developing small molecules and biologics to guide cell fate for therapeutic purposes. Dr Batchelor brings more than 28

Advaxis, a development-stage biotechnology company, has submitted to the FDA its lead drug candidate, ADXS11-001, for orphan drug designation to treat invasive carcinoma of the cervix. The orphan

Aveo Pharmaceuticals, a biotechnology company, has initiated a Phase Ib/IIa clinical trial of AV-951 as monotherapy for the treatment of advanced non-small cell lung cancer. This new trial

US-based Celator Pharmaceuticals has treated the first patient in its Phase II multicenter, randomized, open-label clinical trial of CPX-351 liposome injection versus intensive salvage therapy in adult patients,

According to Bellus Health, the current programs related to the company’s existing product and product candidates will not be affected by the cuts, which are being made primarily

The increase in net loss for the fourth quarter of 2008, as compared to the fourth quarter of 2007, was primarily due to a decrease in interest income

Revenues for the fourth quarter ended December 31, 2008 were $2.9 million, up from $2.1 million for the corresponding period in 2007. Revenues for the full-year 2008 totaled

Drugstore chain Duane Reade Holdings has reported total net sales of $464.5m in the fourth quarter of 2008, an increase of 7.6%, compared to $431.6m in the fourth

Total revenues for the three months ended December 31, 2008 were $6.2 million, compared to $2.2 million for the fourth quarter of 2007. Net income for the year